More Post from the Author
- StarKist, Feed the Children, and Feed 479 Unite to Support 400 Northwest Arkansas Families with Food and Resources
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of EmCentrix Customers Whose Data May Have Been Compromised
- McLaughlin Poll: Voters Overwhelmingly Reject Excessive Government Mandates and Regulatory Red Tape Targeting the Individual Health Care Marketplace
- 50+ Environmental and Public Interest Groups Oppose CA Oil Refiner Bailout, Urge State to Stand Strong on Accountability, Says Consumer Watchdog
- 88 Dragons PR Inc: HISTORIC PEACE AGREEMENT SIGNED BETWEEN DEMOCRATIC REPUBLIC OF CONGO AND RWANDA
Vitrolife AB Fourth quarter and full year report, 2024: A strong finish to the year
Published on Thu 30 Jan 2025 9:24:19 UTC
GOTHENBURG, Sweden, Jan. 30, 2025 /PRNewswire/ -- Fourth quarter
- Sales of SEK 959 (904) million, an increase of 6% in local currencies and 6% in SEK.
- Sales per region, in local currencies was +10% in EMEA, +9% in Americas and -2% in APAC.
- Sales per business area, in local currencies was +12% in Consumables, +9% in Technologies and 0% in Genetics.
- Gross margin increased to 61.1% (56.9).
- Operating income before depreciation and amortisation (EBITDA) increased to SEK 337 (294) million, giving an EBITDA margin of 35.1% (32.5).
- Operating cash flow increased to SEK 268 million (171).
- Net income was SEK 139 (-4,179) million, resulting in earnings per share before dilution of SEK 1.03 (-30.86) and after dilution of SEK 1.02 (-30.86).
- Helena Wennerstrm was appointed acting CFO of Vitrolife AB (publ) effective 3 December 2024.
Full year
- Sales of SEK 3,609 (3,512) million, an increase of 4% in local currencies and 3% in SEK.
- Sales per region, in local currencies was +7% in EMEA, +1% in Americas and +5% in APAC.
- Sales per business area, in local currencies was +10% in Consumables, +16% in Technologies and -5% in Genetics.
- Gross margin increased to 59.3% (56.3).
- Operating income before depreciation and amortisation (EBITDA) increased to SEK 1,225 (1,136) million, giving an EBITDA margin of 34.0% (32.3).
- Operating cash flow increased to SEK 907 million (757).
- Net income was SEK 514 (-3,851) million, resulting in earnings per share before dilution of SEK 3.79 (-28.44) and after dilution of SEK 3.78 (-28.44).
Dividend
- The Board to propose to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.
Gothenburg, January 30, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor,
CEO
The information was submitted for publication, through the agency of the contact persons set out above, at30-01-2025 08:00 CET.
Contact:
Helena Wennerstrm, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Interim report Q4, 2024: A strong finish to the year |
SOURCE Vitrolife AB (publ)

More Post from the Author
- StarKist, Feed the Children, and Feed 479 Unite to Support 400 Northwest Arkansas Families with Food and Resources
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of EmCentrix Customers Whose Data May Have Been Compromised
- McLaughlin Poll: Voters Overwhelmingly Reject Excessive Government Mandates and Regulatory Red Tape Targeting the Individual Health Care Marketplace
- 50+ Environmental and Public Interest Groups Oppose CA Oil Refiner Bailout, Urge State to Stand Strong on Accountability, Says Consumer Watchdog
- 88 Dragons PR Inc: HISTORIC PEACE AGREEMENT SIGNED BETWEEN DEMOCRATIC REPUBLIC OF CONGO AND RWANDA